Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment

American Heart Journal

Volumn 154, Issue 5, 2007, Pages 954-961

  Welten, Gijs M J M ^a   Chonchol, Michel ^b   Hoeks, Sanne E ^a   Schouten, Olaf ^a   Dunkelgrün, Martin ^a   van Gestel, Yvette R B M ^a   Goei, Dustin ^a   Bax, Jeroen J ^c   van Domburg, Ron T ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; VASCULAR SURGERY;

AGED; AORTIC ANEURYSM, ABDOMINAL; CAUSE OF DEATH; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 35549003143     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.040     Document Type: Article

References (29)

1. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
2. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169
3. Kwan B.C., Kronenberg F., Beddhu S., et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18 (2007) 1246-1261
4. Kronenberg F., Kuen E., Ritz E., et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11 (2000) 105-115
5. Kronenberg F., Kuen E., Ritz E., et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 13 (2002) 461-469
6. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 (2005) 24F-33F
7. Levine G.N., Keaney Jr. J.F., and Vita J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332 (1995) 512-521
8. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
9. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41 Suppl 3 (2003) S1-S92
10. Weiner D.E., and Sarnak M.J. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 19 (2004) 1045-1052
11. Tonelli M., Collins D., Robins S., et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66 (2004) 1123-1130
12. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
13. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
14. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
15. Perrone R.D., Madias N.E., and Levey A.S. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38 (1992) 1933-1953
16. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
17. O'Hare A.M., Glidden D.V., Fox C.S., et al. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 109 (2004) 320-323
18. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41 (2003) 47-55
19. Leung W.H., Lau C.P., and Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 341 (1993) 1496-1500
20. Wanner C., Zimmermann J., Schwedler S., et al. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 80 (2002) 99-102
21. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
22. Chonchol M., Cook T., Kjekshus J., et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 49 (2007) 373-382
23. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
24. Gibney E.M., Casebeer A.W., Schooley L.M., et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study. Kidney Int 68 (2005) 826-832
25. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
26. Tsimihodimos V., Kakafika A., and Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 16 (2001) 1301
27. Lipscombe J., Lewis G.F., Cattran D., et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55 (2001) 39-44
28. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
29. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281